Article

Changing Oncology Reimbursement Could Cut Drug Shortages, Lawmakers Told

Reforming oncology reimbursement is one method that could increase incentives to manufacturers and subsequently reduce drug shortages, according to testimony at a Senate Finance Committee hearing.

The hearing addressed causes of the recent drug shortages. About 30% of the drugs in short supply are oncology products.

Oncology drugs are reimbursed according to average sales price and an additional 6% markup that covers practice costs as a result of the Medicare Modernization Act in 2003, according to a perspective published last month in the New England Journal of Medicine. The authors said in the perspective that oncologists have incentive to use brand-name drugs that will provide a higher margin.

Read more: Changing oncology reimbursement could cut drug shortages, lawmakers told

Source: Modern Healthcare

Related Videos
Kim Newcomer, director of volunteers, Colorectal Cancer Alliance
Dr Rebecca Haberman
Susan Escudier, MD, FACP
2 experts in this video
2 experts in this video
Dr Michael Bernstein
Screenshot of an interview with Evangelia Vlachou, MD
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo